Effectiveness of combination of lenvatinib and pembrolizumab in first line therapy of metastatic renal cell carcinoma
https://doi.org/10.33667/2078-5631-2022-26-58-63
Abstract
Due to the promising results of recent trials in the treatment of metastatic renal cell cancer (mRCC) multi-drug regimens combining immunotherapy and targeted therapy in the first line are increasingly recognized. The combinations are already included in international clinical guidelines as preferred treatment options for patients with mRCC. In particular, combination of lenvatinib and pembrolizumab demonstrated high efficacy in terms of achieving a complete response, progression-free survival with a manageable toxicity profile. All adverse events on this therapy are predictable and quite well controlled. We report on our own experience of using lenvatinib plus pembrolizumab combination therapy on the example of two clinical cases of patients with intermediate prognosis mRCC.
Keywords
metastatic renal cell carcinoma,
mRCC,
combination regimens,
lenvatinib,
pembrolizumab,
efficacy,
toxicity,
complete response,
quality of life
Supporting agencies: The article was published with the financial support of Eisai Сo. The authors are solely responsible for the content of the article and editorial decisions.
About the Authors
E. I. Kopyltsov
Clinical Oncology Dispensary
Russian Federation
Russian Federation
Kopyltsov Evgeniy I., PhD Med, head of Urology Dept
Omsk
V. A. Vodolazskiy
Clinical Oncology Dispensary
Russian Federation
Russian Federation
Vodolazskiy Vladislav A., oncologist, Urology Dept
Omsk
M. V. Skoraya
Novosibirsk Regional Clinical Oncology Center
Russian Federation
Russian Federation
Skoraya Marina V., doctor at 3rd Oncology Dept
Novosibirsk
V. V. Kozlov
Novosibirsk Regional Clinical Oncology Center
Russian Federation
Russian Federation
Kozlov Vadim V., PhD Med, head of 3rd Oncology Dept
Novosibirsk
References
1. Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE‑426): extended follow-up from a randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2020 Dec; 21 (12): e553]. Lancet Oncol. 2020; 21 (12): 1563–1573. DOI: 10.1016/S1470–2045(20)30436–8.
2. Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020; 31 (8): 1030–1039. DOI: 10.1016/j.annonc.2020.04.010.
3. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020; 5 (6): e001079. DOI: 10.1136/esmoopen-2020–001079.
4. Motzer RJ, Porta C, Eto M, et al. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). J Clin Oncol. 2021; 39 (suppl 6): 269. DOI: 10.1200/JCO.2021.39.6_suppl.269.
5. Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study [published online ahead of print, 2022 Apr 27]. Lancet Oncol. 2022; S 1470–2045 (22) 00212–1. DOI: 10.1016/S 1470–2045 (22)00212–1.
6. NCCN. Clinical Practice Guidelines in Oncology. Kidney cancer, version 2. 2023. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
7. Powles T, Albiges L, Bex A, et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021; 32 (12): 1511–1519. DOI: 10.1016/j.annonc.2021.09.014.
8. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med. 2021; 384 (14): 1289–1300. DOI: 10.1056/NEJMoa2035716.
9. Ljungberg (Chair) B, Albiges L et al. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN978–94–92671–13–4.
10. Cancer of the parenchyma of the kidney. Clinical recommendations of the Russian Ministry of Health. 2021. Electronic resource. Access mode: https://cr.minzdrav.gov.ru/recomend/10_3 Access date: 08/12/2022.
11. Nosov D. A., Alekseev B. Ya., Volkova M. I., Gladkov O. A., Popov A. M., Kharkevich G. Yu. Practical guidelines for drug treatment of renal cell carcinoma. Malignant Tumors: Practice Guidelines RUSSCO #3s2, 2019 (Volume 9). pp. 498–506.
12. Cancer of the parenchyma of the kidney. Draft clinical guidelines of the Russian Ministry of Health. 2022. Electronic resource. Access mode: https://oncology-association.ru/wp-content/uploads/2022/03/rak-parenhimy-pochki.pdf
13. Omelyanovsky V. V., Maksimkina E.A., Ivakhnenko O. I. et al. Improvement of the system for the formation of lists of medicinal products for medical use: analysis of changes in the Decree of the Government of the Russian Federation No. 871. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2020; 13 (2): 113–123. DOI: https://doi.org/10.17749/2070–4909/farmakoekonomika.2020.032.
14. Kolbin A. S., Gomon Yu.M., Kasimova A.R. et al. The real practice of conducting clinical and economic studies of drugs included in the federal program of high-cost nosologies. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2022; 15 (1): 87–105. DOI: https://doi.org/10.17749/2070–4909/farmakoekonomika.2022.107.
15. Framework for FDA’S Real-World Evidence Program. Режим доступа: https://www.fda.gov/media/120060/download (дата обращения 27.07.2022).
Review
For citations:
Kopyltsov E.I., Vodolazskiy V.A., Skoraya M.V., Kozlov V.V. Effectiveness of combination of lenvatinib and pembrolizumab in first line therapy of metastatic renal cell carcinoma. Medical alphabet. 2022;(26):58-63. (In Russ.) https://doi.org/10.33667/2078-5631-2022-26-58-63
Views:
664
Email this article 